{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:40:41Z","timestamp":1792442441310,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00520-026-11340-3","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:42:09Z","timestamp":1792438929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-1465","authenticated-orcid":false,"given":"Vanessa","family":"Rouach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Versano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meital","family":"Sasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Makori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"11340_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172878","volume":"17","author":"M Brennan","year":"2025","unstructured":"Brennan M, Kalsi T (2025) Management of bone health considerations in patients with cancer. Cancers (Basel) 17. https:\/\/doi.org\/10.3390\/cancers17172878","journal-title":"Cancers (Basel)"},{"key":"11340_CR2","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2213-8587(24)00088-3","volume":"12","author":"CS Link-Rachner","year":"2024","unstructured":"Link-Rachner CS, G\u00f6bel A, Jaschke NP, Rachner TD (2024) Endocrine health in survivors of adult-onset cancer. Lancet Diabetes Endocrinol 12:350\u2013364. https:\/\/doi.org\/10.1016\/S2213-8587(24)00088-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"11340_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(Suppl 1):S3-18. https:\/\/doi.org\/10.1016\/j.ctrv.2008.03.007","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"11340_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crin\u00f2 L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Th\u00fcrlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420\u2013432. https:\/\/doi.org\/10.1093\/annonc\/mdm442","journal-title":"Ann Oncol"},{"issue":"28","key":"11340_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100355.PMID:33948427;PMCID:PMC8080519","volume":"18","author":"K Waqas","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC (2021) Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 18(28). https:\/\/doi.org\/10.1016\/j.jbo.2021.100355.PMID:33948427;PMCID:PMC8080519","journal-title":"J Bone Oncol"},{"issue":"2","key":"11340_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2022.151280","volume":"38","author":"SD Rayner-Myers","year":"2022","unstructured":"Rayner-Myers SD, Hunter K, Pituskin E (2022) Direct and indirect mechanisms of chemotherapy-induced bone loss in adjuvant breast cancer: an integrative review. Semin Oncol Nurs 38(2). https:\/\/doi.org\/10.1016\/j.soncn.2022.151280","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"11340_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11914-013-0174-z","volume":"11","author":"R Pacheco","year":"2013","unstructured":"Pacheco R, Stock H (2013) Effects of radiation on bone. Curr Osteoporos Rep 11(4):299\u2013304. https:\/\/doi.org\/10.1007\/s11914-013-0174-z","journal-title":"Curr Osteoporos Rep"},{"issue":"17","key":"11340_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176377","volume":"21","author":"AJ Donaubauer","year":"2020","unstructured":"Donaubauer AJ, Deloch L, Becker I, Fietkau R, Frey B, Gaipl US (2020) The influence of radiation on bone and bone cells-differential effects on osteoclasts and osteoblasts. Int J Mol Sci 21(17). https:\/\/doi.org\/10.3390\/ijms21176377","journal-title":"Int J Mol Sci"},{"key":"11340_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3892\/mco.2018.1615","volume":"8","author":"CT Axelsen","year":"2018","unstructured":"Axelsen CT, Jensen AB, Jakobsen EH, Bechmann T (2018) Bone loss during neoadjuvant\/adjuvant chemotherapy for early-stage breast cancer. Mol Clin Oncol 8:767\u2013772. https:\/\/doi.org\/10.3892\/mco.2018.1615","journal-title":"Mol Clin Oncol"},{"key":"11340_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-021-05914-z","volume":"32","author":"B Bouvard","year":"2021","unstructured":"Bouvard B, Soulat G, H\u00e9lis V et al (2021) Bone loss and fracture risk after chemotherapy for breast cancer. Osteoporos Int 32:1683\u20131691. https:\/\/doi.org\/10.1007\/s00198-021-05914-z","journal-title":"Osteoporos Int"},{"key":"11340_CR11","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S1470-2045(17)30036-5","volume":"18","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro M, Body JJ et al (2017) Management of aromatase inhibitor\u2013associated bone loss. Lancet Oncol 18:e319\u2013e328. https:\/\/doi.org\/10.1016\/S1470-2045(17)30036-5","journal-title":"Lancet Oncol"},{"issue":"33","key":"11340_CR12","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","volume":"26","author":"F Saad","year":"2008","unstructured":"Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26(33):5465\u201376. https:\/\/doi.org\/10.1200\/JCO.2008.18.4184","journal-title":"J Clin Oncol"},{"issue":"12","key":"11340_CR13","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","volume":"22","author":"P Hadji","year":"2011","unstructured":"Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22(12):2546\u20132555. https:\/\/doi.org\/10.1093\/annonc\/mdr017","journal-title":"Ann Oncol"},{"key":"11340_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00198-023-06672-3","volume":"34","author":"MI Khan","year":"2023","unstructured":"Khan MI (2023) Management of bone loss due to endocrine therapy during cancer treatment. Osteoporos Int 34:671\u2013680. https:\/\/doi.org\/10.1007\/s00198-023-06672-3","journal-title":"Osteoporos Int"},{"key":"11340_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00774-023-01414-1","volume":"41","author":"S Takahashi","year":"2023","unstructured":"Takahashi S (2023) Management of cancer treatment\u2013induced bone loss in breast and prostate cancer. J Bone Miner Metab 41:307\u2013316. https:\/\/doi.org\/10.1007\/s00774-023-01414-1","journal-title":"J Bone Miner Metab"},{"issue":"9","key":"11340_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70873","volume":"14","author":"I Liang","year":"2025","unstructured":"Liang I, Brennan S, Girgis C, Hayden A, Moujaber T, Turner S, Vasista A, Grossmann M, Wong PKK (2025) Bone health management in men commencing androgen deprivation therapy for prostate cancer and women commencing anti-oestrogen therapy for breast cancer. Cancer Med 14(9). https:\/\/doi.org\/10.1002\/cam4.70873","journal-title":"Cancer Med"},{"key":"11340_CR17","doi-asserted-by":"publisher","unstructured":"Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C, Collinson FJ, Coleman RE, James N, Francis R, Reid DM, McCloskey E (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol 25:100311. https:\/\/doi.org\/10.1016\/j.jbo.2020.100311","DOI":"10.1016\/j.jbo.2020.100311"},{"issue":"5","key":"11340_CR18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","volume":"7","author":"C Jones","year":"2024","unstructured":"Jones C, Gray S, Brown M, Brown J, McCloskey E, Rai BP, Clarke N, Sachdeva A (2024) Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials. Eur Urol Oncol 7(5):993\u20131004. https:\/\/doi.org\/10.1016\/j.euo.2024.01.016","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"11340_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-025-01362-0","volume":"116","author":"M Teissonni\u00e8re","year":"2025","unstructured":"Teissonni\u00e8re M, Point M, Biver E, Hadji P, Bonnelye E, Ebeling PR, Kendler D, de Villiers T, Holzer G, Body JJ, Fuleihan GEH, Brandi ML, Rizzoli R, Confavreux CB (2025) Bone effects of anti-cancer treatments in 2024. Calcif Tissue Int 116(1). https:\/\/doi.org\/10.1007\/s00223-025-01362-0","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"11340_CR20","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00198-013-2530-3","volume":"24","author":"R Rizzoli","year":"2013","unstructured":"Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Gl\u00fcer CC, Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, de Villiers TJ, El Hajj Fuleihan G (2013) Cancer-associated bone disease. Osteoporos Int 24(12):2929\u201353. https:\/\/doi.org\/10.1007\/s00198-013-2530-3","journal-title":"Osteoporos Int"},{"issue":"3","key":"11340_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00198-022-06631-4","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye C, Leslie WD (2023) Fracture risk and assessment in adults with cancer. Osteoporos Int 34(3):449\u2013466. https:\/\/doi.org\/10.1007\/s00198-022-06631-4","journal-title":"Osteoporos Int"},{"issue":"2","key":"11340_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00198-020-05596-6","volume":"32","author":"WD Leslie","year":"2021","unstructured":"Leslie WD, Edwards B, Al-Azazi S, Yan L, Lix LM, Czaykowski P, Singh H (2021) Cancer patients with fractures are rarely assessed or treated for osteoporosis: a population-based study. Osteoporos Int 32(2):333\u2013341. https:\/\/doi.org\/10.1007\/s00198-020-05596-6","journal-title":"Osteoporos Int"},{"issue":"3","key":"11340_CR23","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2666-7568(23)00285-4","volume":"5","author":"E Buzasi","year":"2024","unstructured":"Buzasi E, Carreira H, Funston G, Mansfield KE, Forbes H, Strongman H, Bhaskaran K (2024) Risk of fractures in half a million survivors of 20 cancers: a population-based matched cohort study using linked English electronic health records. Lancet Healthy Longev 5(3):e194\u2013e203. https:\/\/doi.org\/10.1016\/S2666-7568(23)00285-4","journal-title":"Lancet Healthy Longev"},{"key":"11340_CR24","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31:1650\u20131663. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"key":"11340_CR25","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C et al (2019) Management of osteoporosis in survivors of adult cancers. J Clin Oncol 37:2916\u20132946. https:\/\/doi.org\/10.1200\/JCO.19.01696","journal-title":"J Clin Oncol"},{"issue":"5","key":"11340_CR26","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"11340_CR27","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00198-017-4218-6","volume":"28","author":"OL Tseng","year":"2017","unstructured":"Tseng OL, Dawes MG, Spinelli JJ, Gotay CC, McBride ML (2017) Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada. Osteoporos Int 28(12):3439\u20133449. https:\/\/doi.org\/10.1007\/s00198-017-4218-6","journal-title":"Osteoporos Int"},{"issue":"5","key":"11340_CR28","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1200\/JOP.2016.018341","volume":"13","author":"J Stratton","year":"2017","unstructured":"Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, Mougalian SS (2017) Bone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors. J Oncol Pract 13(5):e505\u2013e515. https:\/\/doi.org\/10.1200\/JOP.2016.018341","journal-title":"J Oncol Pract"},{"issue":"1","key":"11340_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01430-1","volume":"21","author":"S Bailey","year":"2021","unstructured":"Bailey S, Lin J (2021) The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivors. BMC Womens Health 21(1). https:\/\/doi.org\/10.1186\/s12905-021-01430-1","journal-title":"BMC Womens Health"},{"key":"11340_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100501","volume":"42","author":"V Rouach","year":"2023","unstructured":"Rouach V, Greenman Y, Chodick G, Goldshtein I (2023) DXA assessment and fracture prevention after aromatase inhibitor initiation. J Bone Oncol 42. https:\/\/doi.org\/10.1016\/j.jbo.2023.100501","journal-title":"J Bone Oncol"},{"issue":"4","key":"11340_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bju.14120","volume":"121","author":"SS Harmouch","year":"2018","unstructured":"Harmouch SS, Berger AJ, Cole AP (2018) Low rates of bone density testing in prostate cancer survivors on androgen-deprivation therapy: where do we go from here? BJU Int 121(4):492\u2013493. https:\/\/doi.org\/10.1111\/bju.14120","journal-title":"BJU Int"},{"key":"11340_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630751","volume":"16","author":"JW Wang","year":"2025","unstructured":"Wang JW, Dai MW, Liu JH (2025) The regulatory effects of PD-1\/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management. Front Immunol 16. https:\/\/doi.org\/10.3389\/fimmu.2025.1630751","journal-title":"Front Immunol"},{"issue":"9","key":"11340_CR33","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00198-025-07647-2","volume":"36","author":"V Siampanopoulou","year":"2025","unstructured":"Siampanopoulou V, Ziogas DC, Lyrarakis G, Anastasopoulou A, Kassi E, Gogas H, Angelousi A (2025) Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis. Osteoporos Int 36(9):1711\u20131718. https:\/\/doi.org\/10.1007\/s00198-025-07647-2","journal-title":"Osteoporos Int"},{"issue":"1","key":"11340_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2025-000868","volume":"4","author":"MP Yavropoulou","year":"2025","unstructured":"Yavropoulou MP, Anastasilakis DA, Kasdagli MI, Gialouri CG, Palaiopanos K, Fountas A, Anastasilakis AD, Daskalakis K, Dekkers OM, Lems WF, Papapoulos SE, Makras P (2025) Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trials. BMJ Open Oncol 4(1). https:\/\/doi.org\/10.1136\/bmjonc-2025-000868","journal-title":"BMJ Open Oncol"},{"key":"11340_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1475-9276-8-19","volume":"8","author":"O Baron-Epel","year":"2009","unstructured":"Baron-Epel O, Friedman N, Lernau O (2009) Reducing disparities in mammography-use in a multicultural population in Israel. Int J Equity Health 8. https:\/\/doi.org\/10.1186\/1475-9276-8-19","journal-title":"Int J Equity Health"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11340-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11340-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11340-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:42:10Z","timestamp":1792438930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11340-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11340"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11340-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed by the Assuta Medical Centers Institutional Review Board and was granted exemption from formal ethical approval due to the use of fully anonymized retrospective data. Informed consent was waived in accordance with institutional and national guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the author (Vanessa Rouach) used ChatGPT (OpenAI) to assist with language editing and refinement of the text. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1124"}}